Piroxicam Tablets

[Pharmacology and Toxicology] It is a non-steroidal anti-inflammatory drug with analgesic, anti-inflammatory and antipyretic effects. This product exerts its pharmacological effects by inhibiting cyclooxygenase to reduce the synthesis of local prostaglandins in tissues, inhibiting the chemotaxis of leukocytes and the release of lysosomal enzymes. Results of acute toxicity test: The oral LD50 of mice is 360mg/kg. [Pharmacokinetics] Good oral absorption. Food can reduce the absorption rate, but does not affect the total amount of absorption. The plasma protein binding rate is as high as more than 90%. Metabolized by the liver. The average T1/2 is 50 hours (30-86 hours), and the T1/2 is prolonged in patients with renal insufficiency. Due to the long half-life, a single dose can maintain a relatively stable blood drug concentration for 24 hours, and multiple doses are prone to accumulation. A single dose of 20mg, the blood drug concentration reaches the peak in 3-5 hours, and the effective blood drug concentration is 1.5-2μg/ml. The stable blood drug concentration can be reached 7-12 days after the start of treatment. 66% is excreted from the kidneys, 33% is excreted from the feces, and 5% is in its original form.

The main ingredients of this product and their chemical names are: The main ingredient of this product is piroxicam, and its chemical name is 2-methyl-4-hydroxy-N-(2-pyridyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide.

This product is an off-white, slightly yellowish green tablet or a sugar-coated tablet. After removing the sugar coating, it appears off-white or slightly yellowish green.

Used for symptomatic treatment of pain and swelling in various arthritis and soft tissue lesions.

Oral administration, usual adult dose: 20 mg once a day, or 10 mg twice a day. Take after meals.

(1) Gastrointestinal adverse reactions such as nausea, stomach pain, decreased appetite and indigestion are the most common, of which 3.5% require drug withdrawal. The incidence of gastric ulcer increases significantly when the dosage is greater than 20 mg per day, and some are accompanied by bleeding or even perforation. (2) Neutropenia, eosinophilia, increased blood urea nitrogen, dizziness, vertigo, tinnitus, headache, general weakness, edema, rash or itching, etc. (3) Abnormal liver function, thrombocytopenia, hyperhidrosis, skin ecchymosis, peeling, erythema multiforme, toxic epithelial necrosis, bullous erythema multiforme (Stevens-Johnson syndrome), skin allergic reaction to light, blurred vision, red and swollen eyes, hypertension, hematuria, hypoglycemia, depression, insomnia and mental tension, etc.

It is contraindicated for patients who are allergic to this product, have peptic ulcers, or chronic gastric diseases.

Precautions for children: Forbidden. Precautions for pregnancy and lactation: 1. Pregnant women who take the drug in the last month of pregnancy may inhibit labor and cause dystocia. At the same time, gastrointestinal toxicity may occur. In addition, long-term use of the drug in the late pregnancy may cause early closure or stenosis of the fetal arterial ductus, resulting in persistent pulmonary hypertension and heart failure in the newborn. Pregnant women are prohibited from using it. 2. Piroxicam tablets can cause a decrease in milk secretion, which is related to the dosage. It is not suitable for lactating women. Precautions for the elderly: Use with caution.

(1) When taken with alcohol or other anti-inflammatory drugs, gastrointestinal adverse reactions increase. (2) When used with anticoagulants such as dicoumarol, the latter's effect is enhanced and bleeding tendency is significant, so the dosage should be adjusted. (3) When used with aspirin, the blood concentration of this product can drop to 80% of the normal concentration, and the risk of gastrointestinal ulcer formation and bleeding tendency increases.

Keep away from light and store in sealed container.

20mg

36 months

Beijing Jingfeng Pharmaceutical Co., Ltd.

• Founded in:

  2002-03-06

• Address:

  Building 1, Building 9-10, Building 12-13, No. 21, Xiangrui Street, Daxing Biomedicine Industry Base, Zhongguancun Science Park, Daxing District, Beijing

• Tax NO.:

  91110000736469100Q

• Registered Funds:

  475.3425 million yuan

• Website:

  Log in to view

• Email:

  Log in to view